Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015937 | 0.85 | HRH4 (0.46) | HTR2CHTR1ADRD2 | |
| SCHEMBL1775605 | 0.83 | HTR6 (0.56) | HTR2CHTR6HTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL1775612 | 0.82 | HTR6 (0.55) | HTR2CHTR6HTR1ADRD2HTR7 | |
| SCHEMBL6385040 | 0.82 | HTR6 (0.47) | HTR2CHTR6HTR1ADRD2HTR7 | |
| SCHEMBL1776417 | 0.81 | HTR6 (0.48) | HTR2CHTR6 | |
| SCHEMBL6382957 | 0.81 | HTR6 (0.47) | HTR2CHTR6 | |
| SCHEMBL1777202 | 0.81 | HTR6 (0.48) | HTR2CHTR6HTR1AHTR7 | |
| SCHEMBL1776290 | 0.81 | HTR6 (0.52) | HTR2CHTR6HTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL1774476 | 0.80 | HTR6 (0.47) | HTR2CHTR6 | |
| Hydrochloric Acid SCHEMBL1775919 | 0.80 | HTR6 (0.47) | HTR2CHTR6HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | claimed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | claimed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HTR2C 1245/4885HTR6 2109/4885HTR1A 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.